Health Care & Life Sciences » Biotechnology | TapImmune Inc.

TapImmune Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
SG&A Expense
2,664.30
3,370.90
6,159.00
8,492.30
11,663.10
EBIT
2,664.30
3,370.90
6,159.00
8,492.30
11,663.10
Unusual Expense
1,117.70
26,883.70
27,872.60
5,803.90
497.90
Non Operating Income/Expense
5.90
53.00
23.90
1.80
-
Interest Expense
1,756.40
575.50
10.90
-
-
Pretax Income
5,532.60
30,883.10
34,066.40
2,455.40
10,982.20
Consolidated Net Income
5,532.60
30,883.10
34,066.40
2,455.40
10,982.20
Net Income
5,532.60
30,883.10
34,066.40
2,455.40
10,982.20
Net Income After Extraordinaries
5,532.60
30,883.10
34,066.40
2,455.40
10,982.20
Net Income Available to Common
5,532.60
30,883.10
34,066.40
2,455.40
10,982.20
EPS (Basic)
58.44
23.96
9.36
0.72
1.16
Basic Shares Outstanding
94.70
1,288.80
3,662.30
6,889.90
9,453.50
EPS (Diluted)
58.44
23.96
9.30
0.72
1.16
Diluted Shares Outstanding
94.70
1,288.80
3,662.30
7,421.00
9,453.50
EBITDA
2,664.30
3,370.90
6,159.00
8,492.30
11,663.10

About TapImmune

View Profile
Address
5 West Forsyth Street
Jacksonville Florida 32202
United States
Employees -
Website http://www.tapimmune.com
Updated 09/14/2018
TapImmune, Inc. is an immuno-oncology company, which engages in the development of technologies for the treatment of cancer, including metastasis, and infectious diseases. It also involves in developing vaccines for breast, colorectal, ovarian, and non-small cell lung cancer. The company was founded in 1991 and is headquartered in Jacksonville, FL.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.